Screening tests of platelet function: Update on their appropriate uses for diagnostic testing

Seminars in Thrombosis and Hemostasis

Volumn 35, Issue 2, 2009, Pages 150-157

  Harrison, Paul ^a   Mumford, Andrew ^b  

^a CHURCHILL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Bleeding time; PFA 100; Platelet counting; Platelet disorders; Platelet function testing

Indexed keywords

VON WILLEBRAND FACTOR;

BERNARD SOULIER DISEASE; BLEEDING; BLEEDING TIME; BLOOD CLOTTING TEST; DIAGNOSTIC TEST; GLANZMANN DISEASE; HUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; REVIEW; SCREENING TEST; THROMBOCYTE COUNT; THROMBOCYTE DISORDER; THROMBOCYTE FUNCTION; VON WILLEBRAND DISEASE; BLOOD; BLOOD CLOTTING DISORDER; BLOOD CLOTTING PARAMETERS; MASS SCREENING; METHODOLOGY; STANDARD;

BLOOD COAGULATION DISORDERS; MASS SCREENING; PLATELET FUNCTION TESTS;

EID: 63149094900     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0029-1220323     Document Type: Review

References (68)

1. Hayward CP. Diagnostic approach to platelet function disorders. Transfus Apheresis Sci 2008;38:65-76
2. Cattaneo M. Inherited platelet-based bleeding disorders. J Thromb Haemost 2003;1:1628-1636
3. Quiroga T, Goycoolea M, Panes O, et al. High prevalence of bleeders of unknown cause among patients with inherited mucocutaneous bleeding. A prospective study of 280 patients and 299 controls. Haematologica 2007;92:357-365
4. Zeidan AM, Kouides PA, Tara MA, Fricke WA. Platelet function testing: state of the art. Expert Rev Cardiovasc Ther 2007;5:955-967 (Pubitemid 47499966)
5. Laffan M, Brown SA, Collins PW, et al. The diagnosis of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organization. Haemophilia 2004;10:199-217 (Pubitemid 38584792)
6. Bolton-Maggs PH, Perry DJ, Chalmers EA, et al. The rare coagulation disorders-review with guidelines for management from the United Kingdom Haemophilia Centre Doctors' Organisation. Haemophilia 2004;10:593-628
7. Cattaneo M. Light transmission aggregometry and ATP release for the diagnostic assessment of platelet function. Semin Thromb Hemost 2009;35:158-167
8. McGlasson D, Fritsma GA. Whole blood platelet aggregometry and platelet function testing. Semin Thromb Hemost 2009;35:168-180
9. Varon D, Savion N. Impact Cone and Plate(let) Analyzer. In: Michelson, AD, ed. Platelets. San Diego, CA: Academic Press; 2007:535-544
10. Harrison P, Frelinger AL III, Furman MI, Michelson AD. Measuring antiplatelet drug effects in the laboratory. Thromb Res 2007;120:323-336 (Pubitemid 46879909)
11. Duke WW. The relation of blood platelets to hemorrhagic disease. Description of a method for determining the bleeding time and the coagulation time and report of three cases of hemorrahagic disease relieved by blood transfusion. JAMA 1910;55:1185-1192
12. Mielke CH. Measurement of the bleeding time. Thromb Haemost 1984;52:210-211
13. The British Society for Haematology BCSH Haemostasis and Thrombosis Task Force. Guidelines on platelet function testing. J Clin Pathol 1988;41:1322-1330
14. Jennings I, Woods TA, Kitchen S, Walker ID. Platelet function testing: practice among UK National External Quality Assessment Scheme for Blood Coagulation participants, 2006. J Clin Pathol 2008;61:950-954
15. Rodgers RP, Levin J. A critical reappraisal of the bleeding time. Semin Thromb Hemost 1990;16:1-20
16. Peterson P, Hayes TE, Arkin CF, et al. The preoperative bleeding time test lacks clinical benefit: College of American Pathologists' and American Society of Clinical Pathologists' position article. Arch Surg 1998;133:134-139 (Pubitemid 28092910)
17. Quiroga T, Goycoolea M, Munoz B, et al. Template bleeding time and PFA-100 have low sensitivity to screen patients with hereditary mucocutaneous hemorrhages: comparative study in 148 patients. J Thromb Haemost 2004;2:892-898 (Pubitemid 40185736)
18. Podda GM, Bucciarelli P, Lussana F, Lecchi A, Cattaneo M. Usefulness of PFA-100 testing in the diagnostic screening of patients with suspected abnormalities of hemostasis: comparison with the bleeding time. J Thromb Haemost 2007;5:2393-2398 (Pubitemid 350154348)
19. Posan E, McBane RD, Grill DE, Motsko CL, Nichols WL. Comparison of PFA-100 testing and bleeding time for detecting platelet hypofunction and von Willebrand disease in clinical practice. Thromb Haemost 2003;90:483-490 (Pubitemid 37138774)
20. Quick AJ. The bleeding time as a test of hemostatic function. Am J Clin Pathol 1975;64:87-94
21. Kerenyi A, Schlammadinger A, Ajzner E, et al. Comparison of PFA-100 closure time and template bleeding time of patients with inherited disorders causing defective platelet function. Thromb Res 1999;96:487-492
22. Lind SE. The bleeding time does not predict surgical bleeding. Blood 1991;77:2547-2552
23. Harrison P. Progress in the assessment of platelet function. Br J Haematol 2000;111:733-744
24. Kratzer MA, Born GV. Simulation of primary haemostasis in vitro. Haemostasis 1985;15:357-362
25. Kundu SK, Heilmann EJ, Sio R, et al. Description of an in vitro platelet function analyzer-PFA-100. Semin Thromb Hemost 1995;21(Suppl 2):106-112
26. Jilma B. Platelet function analyzer (PFA-100): a tool to quantify congenital or acquired platelet dysfunction. J Lab Clin Med 2001;138:152-163 (Pubitemid 32812228)
27. Moffat KA, Ledford-Kraemer MR, Nichols WL, Hayward CP. Variability in clinical laboratory practice in testing for disorders of platelet function: results of two surveys of the North American Specialized Coagulation Laboratory Association. Thromb Haemost 2005;93:549-553
28. Harrison P, Robinson MS, Mackie IJ, et al. Performance of the platelet function analyser PFA-100 in testing abnormalities of primary haemostasis. Blood Coagul Fibrinolysis 1999;10:25-31 (Pubitemid 29166541)
29. Heilmann EJ, Kundu SK, Sio R, et al. Comparison of four commercial citrate blood collection systems for platelet function analysis by the PFA-100 system. Thromb Res 1997;87:159-164 (Pubitemid 27333273)
30. Dyszkiewicz-Korpanty A, Quinton R, Yassine J, Sarode R. The effect of a pneumatic tube transport system on PFA-100 trade mark closure time and whole blood platelet aggregation. J Thromb Haemost 2004;2:354-356 (Pubitemid 40186055)
31. Harrison P. In vitro measurement of high-shear platelet adhesion and aggregation by the PFA-100. Methods Mol Biol 2004;272:215-223
32. Hayward CP, Eikelboom J. Platelet function testing: quality assurance. Semin Thromb Hemost 2007;33:273-282 (Pubitemid 46581382)
33. Favaloro EJ. Clinical utility of the PFA-100. Semin Thromb Hemost 2008;34:709-733
34. Bock M, De Haan J, Beck KH, et al. Standardization of the PFA-100(R) platelet function test in 105 mmol/l buffered citrate: effect of gender, smoking, and oral contraceptives. Br J Haematol 1999;106:898-904 (Pubitemid 29463001)
35. Sestito A, Sciahbasi A, Landolfi R, et al. A simple assay for platelet-mediated hemostasis in flowing whole blood (PFA-100): reproducibility and effects of sex and age. Cardiologia 1999;44:661-665
36. Carcao MD, Blanchette VS, Dean JA, et al. The Platelet Function Analyzer (PFA-100): a novel in-vitro system for evaluation of primary haemostasis in children. Br J Haematol 1998;101:70-73
37. Dalby MC, Davidson SJ, Burman JF, Davies SW. Diurnal variation in platelet aggregation iwth the PFA-100 platelet function analyser. Platelets 2000;11:320-324
38. Lippi G, Franchini M, Brocco G, Manzato F. Influence of the ABO blood type on the platelet function analyzer PFA-100. Thromb Haemost 2001;85:369-370 (Pubitemid 32140587)
39. Jilma B. Synergistic antiplatelet effects of clopidogrel and aspirin detected with the PFA-100 in stroke patients. Stroke 2003;34:849-854 (Pubitemid 36402950)
40. Hayward CP, Harrison P, Cattaneo M, Ortel TL, Rao AK. Platelet function analyser (PFA-100) closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemost 2006;4:312-319
41. Lasne D, Fiemeyer A, Chatellier G, et al. A study of platelet functions with a new analyzer using high shear stress (PFA 100) in patients undergoing coronary artery bypass graft. Thromb Haemost 2000;84:794-799 (Pubitemid 30946939)
42. Pihusch R, Rank A, Gohring P, et al. Platelet function rather than plasmatic coagulation explains hypercoagulable state in cholestatic liver disease. J Hepatol 2002;37:548-555 (Pubitemid 35305532)
43. Escolar G, Cases A, Vinas M, et al. Evaluation of acquired platelet dysfunctions in uremic and cirrhotic patients using the platelet function analyzer (PFA-100): influence of hematocrit elevation. Haematologica 1999;84:614-619 (Pubitemid 29334317)
44. Pearson DA, Paglieroni TG, Rein D, et al. The effects of flavanol-rich cocoa and aspirin on ex vivo platelet function. Thromb Res 2002;106:191-197 (Pubitemid 35248051)
45. Harrison P. The role of PFA-100 testing in the investigation and management of haemostatic defects in children and adults. Br J Haematol 2005;130:3-10 (Pubitemid 40979127)
46. Franchini M. The platelet function analyzer (PFA-100): an update on its clinical use. Clin Lab 2005;51:367-372 (Pubitemid 41179669)
47. Favaloro EJ. The utility of the PFA-100 in the identification of von Willebrand disease: a concise review. Semin Thromb Hemost 2006;32:537-545 (Pubitemid 44157393)
48. Moeller A, Weippert-Kretschmer M, Prinz H, Kretschmer V. Influence of ABO blood groups on primary hemostasis. Transfusion 2001;41:56-60 (Pubitemid 32142246)
49. Cattaneo M, Federici AB, Lecchi A, et al. Evaluation of the PFA-100 system in the diagnosis and therapeutic monitoring of patients with von Willebrand disease. Thromb Haemost 1999;82:35-39 (Pubitemid 29368770)
50. Favaloro EJ, Kershaw G, Bukuya M, Hertzberg M, Koutts J. Laboratory diagnosis of von Willebrand disorder (vWD) and monitoring of DDAVP therapy: efficacy of the PFA-100 and vWF:CBA as combined diagnostic strategies. Haemophilia 2001;7:180-189 (Pubitemid 32243801)
51. Franchini M, Gandini G, Manzato F, Lippi G. Evaluation of the PFA-100 system for monitoring desmopressin therapy in patients with type 1 von Willebrand's disease. Haematologica 2002;87:670 (Pubitemid 34640657)
52. van Vliet HH, Kappers-Klunne MC, Leebeek FW, Michiels JJ. PFA-100 monitoring of von Willebrand factor (VWF) responses to desmopressin (DDAVP) and factor VIII/VWF concentrate substitution in von Willebrand disease type 1 and 2. Thromb Haemost 2008;100:462-468
53. Mammen EF, Comp PC, Gosselin R, et al. PFA-100 system: a new method for assessment of platelet dysfunction. Semin Thromb Hemost 1998;24:195-202 (Pubitemid 28180831)
54. Harrison P, Robinson M, Liesner R, et al. The PFA-100: a potential rapid screening tool for the assessment of platelet dysfunction. Clin Lab Haematol 2002;24:225-232 (Pubitemid 34989253)
55. Cattaneo M. Are the bleeding time and PFA-100 useful in the initial screening of patients with mucocutaneous bleedings of hereditary natured? J Thromb Haemost 2004;2:890-891
56. Harrison P, Segal H, Furtado C, et al. High incidence of defective high-shear platelet function among platelet donors. Transfusion 2004;44:764-770 (Pubitemid 38608256)
57. Karger R, Donner-Banzhoff N, Muller HH, Kretschmer V, Hunink M. Diagnostic performance of the platelet function analyzer (PFA-100) for the detection of disorders of primary haemostasis in patients with a bleeding history-a systematic review and meta-analysis. Platelets 2007;18:249-260 (Pubitemid 46854816)
58. James AH, Lukes AS, Brancazio LR, Thames E, Ortel TL. Use of a new platelet function analyzer to detect von Willebrand disease in women with menorrhagia. Am J Obstet Gynecol 2004;191:449-455 (Pubitemid 39178697)
59. Philipp CS, Miller CH, Faiz A, et al. Screening women with menorrhagia for underlying bleeding disorders: the utility of the platelet function analyser and bleeding time. Haemophilia 2005;11:497-503 (Pubitemid 41283119)
60. Acharya S, Barraclough J, Ibrahim MS, et al. The usefulness of the platelet function analyser (PFA-100) in screening for underlying bleeding disorders in women with menorrhagia. J Obstet Gynaecol 2008;28:310-314 (Pubitemid 351873809)
61. Jilma-Stohlawetz P, Hergovich N, Homoncik M, et al. Impaired platelet function among platelet donors. Thromb Haemost 2001;86:880-886
62. Curvers J, Dielis AW, Heeremans J, van Wersch JW. Platelet function in whole-blood donors is impaired: the effects of painkillers. Transfusion 2007;47:67-73 (Pubitemid 46006311)
63. Koscielny J, Ziemer S, Radtke H, et al. A practical concept for preoperative identification of patients with impaired primary hemostasis. Clin Appl Thromb Hemost 2004;10:195-204 (Pubitemid 38982043)
64. Koscielny J, von Tempelhoff GF, Ziemer S, et al. A practical concept for preoperative management of patients with impaired primary hemostasis. Clin Appl Thromb Hemost 2004;10:155-166 (Pubitemid 38490084)
65. Bolton-Maggs PH, Chalmers EA, Collins PW, et al. A review of inherited platelet disorders with guidelines for their management on behalf of the UKHCDO. Br J Haematol 2006;135:603-633
66. Harrison P, Briggs C, Machin SJ. Platelet counting. Methods Mol Biol 2004;272:29-46
67. Briggs C, Harrison P, Machin SJ. Platelet counting. In: Michelson AD, ed. Platelets. San Diego, CA: Academic Press; 2007:475-483
68. Althaus K, Greinacher A. MYH9-related platelet disorders. Semin Thromb Hemost 2009;35:189-203